Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide

American Journal of Health-System Pharmacy

Volumn 65, Issue 16, 2008, Pages 1552-1555

  Ip, Eric J ^a,b   Lee Ma, Annette ^b   Troxell, Lawrence S ^b   Chan, James ^b  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Cyclophosphamide; Docetaxel; Dosage; Doxorubicin; Drug comparisons; Filgrastim; Hematopoietic agents; Lenograstim; Neutropenia; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

EID: 50249172718     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070489     Document Type: Article

References (18)

1. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414-22.
2. Morstyn G, Campbell L, Lieschke G et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol. 1989;7:1554-62.
3. Weite K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996; 88:1907-29.
4. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70.
5. Pettengell R, Gurney H, Radford JA et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80:1430-6.
6. Seymour AM, de Campos E, Thatcher N et al. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Eur J Cancer. 1995; 31A:2157-63.
7. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993; 29A:319-24.
8. Gatzemeier U, Kleisbauer JP, Drings P et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol. 2000; 23:393-400.
9. Bohlius J, Reiser M, Schwarzer G et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2004; 3:CD003189.
10. Boogaerts M, Cavalli F, Cortés-Funes H et al. Granulocyte growth factors: achieving a consensus. Ann Oncol. 1995; 6:237-44.
11. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24:3187-205.
12. Crawford J, Althaus B, Armitage J et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007; 5:188-202.
13. Juan O, Campos JM, Caranana V et al. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of postchemotherapy neutropenia. Support Care Cancer. 2001; 9:241-6.
14. Toner GC, Shapiro JD, Laidlaw CR et al. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol. 1998; 16:3874-9.
15. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352:2302-13.
16. Martin M, Lluch A, Segui MA et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006; 17:1205-12.
17. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events. http://ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 2008 Jun 24).
18. Papaldo P, Lopez M, Marolla P et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908-18.